SEC Form 4 · accession 0001209191-15-025518
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Fourteau
Director
Period of report
Mar 11, 2015
Accepted (ET)
Mar 12, 2015 · 10:36 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 11, 2015 | S | 10,000 | $59.9359 | D | 70,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The weighted average sales price for the transaction reported was $59.9359, and the range of prices were between $59.50 to $60.15.